NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $4.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Practice this question and more.

What is a unique risk associated with the patch (CHC) not typically seen with other forms of contraceptive?

Increased risk of vitamin D deficiency
Higher systemic estrogen exposure
Lower risk of blood clots
No risk of interaction with other medications

The correct answer is: Higher systemic estrogen exposure

One unique risk associated with the contraceptive patch (CHC) that is not typically seen with other forms of contraceptives is higher systemic estrogen exposure. The patch delivers hormones directly into the bloodstream through the skin, leading to higher levels of estrogen compared to oral contraceptives. This increased estrogen exposure can potentially increase the risk of certain side effects and complications. Options A, C, and D are incorrect: A. Increased risk of vitamin D deficiency is not a unique risk associated with the contraceptive patch specifically. Vitamin D deficiency can occur due to various reasons unrelated to the type of contraceptive method used. C. Lower risk of blood clots is not a unique risk associated with the patch. In fact, CHCs (combined hormonal contraceptives) carry the risk of blood clots, albeit the risk is generally considered low in healthy women. D. The statement about no risk of interaction with other medications is incorrect. Like other forms of contraceptives, the patch can potentially interact with other medications, leading to reduced effectiveness or increased side effects.